Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Adjuvant gemcitabine for pancreatic cancer
Potential practice changing Update on Pancreatic cancer from ASCO 2013
Commentary for pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreatico-duodenectomy for pancreatic or periampullary tumours: a multicentre randomized trial
Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
Commentary on Induction Gemcitabine and Oxaliplatin Therapy Followed by a Twice-Weekly Infusion of Gemcitabine and Concurrent external-Beam Radiation for Neoadjuvant Treatment of Locally Advanced Pancreatic Cancer (Leone et al, Cancer; 2013 Jan 15;119(2):277-84)
Randomized, placebo-controlled, double-blind, parallel-group phase III study evaluating Aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. By Chang DK et al . JCO 2013,31;1-9
Commentary on SCALOP trial: a multicentre, randomised, phase 2 trial. The Lancet Oncology. 2013 Apr;14(4):317-26.
Malignant Progression in IPMN: A Cohort Analysis of Patients Initially Selected for Resection or Observation. J. LaFemina et al. Ann Surg Oncol 2012
Pancreatic Cancers and the Role of EGFR Pathway
Radiotherapy Technical Considerations in the Management of Locally Advanced Pancreatic Cancer:American-French Consensus Recommendations (IJROBP 2011)
Expert commentary on “New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel” Ann Oncology 2012; 23: 570-6.
Incidental Nonfunctional Pancreatic Endocrine Tumors (NPET) -
Tumor behavior, Clinical management and Outcome.
Adjuvant S1 significantly prolongs overall survival over standard of care Gemcitabine: ASCO GI Abstract 145
Abraxane combination improves outcome in advanced pancreatic cancer